Joint Publicity. No party to this Agreement shall issue any press release or make a public announcement prior to or on the Closing Date concerning this Agreement or the transactions contemplated hereby without the prior approval of Buyer and each of the Shareholders, which approval shall not be unreasonably withheld.
Joint Publicity. If either Party wishes to make a public announcement concerning this Agreement or the relationship established hereunder and such disclosure mentions the other Party by name or description or incorporates that Party’s trademarks, service marks, logos or other similar marks, the Party seeking to make the public announcement will provide other Party \ with an advance copy of the disclosure and the other Party shall have five (5) business days within which to approve or disapprove such use of its name or description (including mention of the name of a Product). Approval shall not be unreasonably withheld by either Party. Absent approval, no public disclosure shall use the name or marks of or otherwise describe such Party except to the extent required by Applicable Law, or to the extent that the description of the other Party is limited to public information about the availability of the Product. The foregoing shall not prohibit Distributor’s use of MDCO’s names or marks in connection with the performance of the services in a manner consistent with this Agreement. All pricing and payment terms in this Agreement are confidential. Except as set forth in Section 9.0 of this Agreement, a Party will remove such information (or request confidential treatment) if it discloses this Agreement for any reason, including in a Securities Exchange Commission filing. Notwithstanding the foregoing, Distributor may publicly disclose that it is an authorized distributor of record for the Product, and MDCO shall comply with all Applicable Laws requiring it to publicly disclose that Distributor is an authorized distributor of record for the Product.
Joint Publicity. The Parties may, within ninety (90) days of signature of this Agreement, jointly announce the existence of this agreement publicly as a license agreement between S3 Group and Licensee for the S3 Group Licensed Materials. Subject thereto, neither party shall mention the other party in any press release or other communication to the public in connection with the Agreement without the prior approval of the other (such approval not to be unreasonably withheld or delayed), and each party shall provide an advance copy of such press release or other communication to facilitate such approval.
Joint Publicity. Within 30 days after the Software licensed under this Agreement is delivered, Client agrees to cooperate with InterWorld to create and issue a joint press release stating that Client is using InterWorld Software. Such press release shall, at a minimum, describe the nature of the business relationship and Client's use of the Software. Such press release is subject to final approval by Client, which approval shall not be unreasonably withheld, InterWorld may thereafter identify Client as a licensee of the Software in its advertising and marketing materials.
Joint Publicity. 8.1.1 The <Department Short Name>, RISL and XxXX would also ensure necessary publicity on the RTI & <Department Short Name> website/e-Mitra/CSC portal and the kiosks running in the State.
Joint Publicity. 12.1 If either Party wishes to make a public announcement concerning this Agreement or the relationship established hereunder and such disclosure mentions the other Party by name or description, such other Party shall be provided with an advance copy of the disclosure and shall have [**] within which to approve or disapprove such use of its name or description (including mention of the name of a Product). Approval shall not be unreasonably withheld by either Party. Absent approval, no public disclosure shall use the name of or otherwise describe such Party except to the extent required by law, or to the extent that the description of the other Party is limited to public information about the availability of a Product.
Joint Publicity. The Parties acknowledge that they each intend to issue press and public announcements relating to this Agreement. The content of all such announcements shall be made only with the prior written approval of the other Party, such approval not to be unreasonably withheld or delayed. Nothing in this Clause 13 shall prevent the making of any announcements which are required by law or by any competent regulatory body, but the Party required to make the announcement agrees to give the other Party the opportunity to review and comment upon the content of the announcement prior to its release. It is agreed that any public announcements will not include commercial or confidential information about the other party.
Joint Publicity. If either party wishes to make a public disclosure concerning this Agreement or the relationship established hereunder and such disclosure mentions the other party by name or description, such other party shall be provided with an advance copy of the disclosure and shall have five (5) business days within which to approve or disapprove such use of its name or description (including mention of the name of the Products). Approval shall not be unreasonably withheld by either party. Failure to respond within such five (5) business days shall be deemed to be approval. Absent approval, no public disclosure shall use the name of or otherwise describe such party except to the extent required by law, or to the extent that the description of the other party is limited to public information about the availability of the Products. Notwithstanding the foregoing, Distributor acknowledges that Cytomedix is a publicly traded Company, and hereby consents to Cytomedix's disclosure of this Agreement and its relationship with Distributor in its filings with the Securities and Exchange Commission and its disclosures to its stockholders and other investors; provided, however, that Cytomedix shall use its commercially reasonable efforts to disclose only those specific financial terms and conditions of this Agreement that are required by applicable law and regulations including, among others, security laws and full disclosure laws and regulations, contractual obligations or business considerations deemed important by Cytomedix.
Joint Publicity. 18.1 At COMPANY discretion, Xansa shall obtain a non-exclusive, non-transferable right to use COMPANY'S name and logo solely in connection with the promotion of the services provided by Xansa pursuant to this Agreement. Xansa will adhere to COMPANY's guidelines in logo, brand and trademark usage. Any use of COMPANY's logo and name must be approved, in advance, by a designated representative of COMPANY's Marketing Department. Both parties shall work together in good faith in collaborative promotion and marketing, including but not limited to:
18.1.1 the issuing of mutually agreed press release(s) announcing the relationship established between the parties by this Agreement;
18.1.2 the preparation and release of joint press announcement(s) relating to the services offered by Xansa to COMPANY;
18.1.3 the appointment by each party of a designated marketing representative within each organization; and
18.1.4 joint attendance at marketing events.
Joint Publicity. If either Party wishes to make significant public disclosure exclusive of correspondence and written communication in the ordinary course of business, concerning this Agreement or the relationship established hereunder and such disclosure mentions the other Party by name or description, such other Party shall be provided in advance with a copy of the disclosure and shall have five (5) business days within which to approve or disapprove of such use of its name or description (including the mentioning of the name of the Product and/or reference to a description of the terms of this Agreement or to any of the exhibits to this Agreement that are incorporated by reference hereto). Neither party shall unreasonably withhold such approval. Failure to respond within said time shall be deemed to constitute an approval. Absent approval, no public disclosure shall use the name of or otherwise describe such Party except to the extent as may be required by law in the reasonable judgment of the respective Party’s counsel, or to the extent that the description of the other Party is limited to public information about the availability of the Product.
